Merck upgraded by HSBC Securities with a new price target
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
HSBC Securities upgraded Merck from Hold to Buy and set a new price target of $130.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $95.00 | Neutral | Citigroup |
| 9/17/2025 | $90.00 | Buy → Hold | Berenberg |
| 5/14/2025 | $84.00 | Buy → Neutral | Citigroup |
| 4/22/2025 | $85.00 | Neutral | Cantor Fitzgerald |
| 2/18/2025 | $128.00 → $105.00 | Buy → Hold | Deutsche Bank |
| 2/10/2025 | $121.00 → $100.00 | Buy → Hold | TD Cowen |
| 1/8/2025 | $110.00 | Buy → Hold | Truist |
| 12/20/2024 | $136.00 → $105.00 | Outperform → Market Perform | BMO Capital Markets |
BOSTON, Oct. 23, 2025 /PRNewswire/ -- eschbach is pleased to share that Merck (NYSE:MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations. This implementation supports Merck's continued drive for greater transparency, responsiveness, and efficiency throughout its supply chain. With Shiftconnector now serving as its found
Results from the Phase 3 CORALreef Lipids and HeFH trials of investigational oral PCSK9 inhibitor enlicitide decanoate will be presented for the first time Presentations across hypercholesterolemia and pulmonary arterial hypertension (PAH) underscore Merck's continued commitment to research with the goal of helping address the cardiovascular (CV) epidemic and significant burden of cardio-pulmonary diseases on public health Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company's cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from
Applications based on Phase 3 KEYNOTE-905 results showing the combination improved event-free survival by 60%, reduced the risk of death by 50% and increased pathologic complete response rates by 48% compared with surgery alone If approved, these would be the first and only perioperative regimens to have improved survival in this patient population Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination wi
8-K - Merck & Co., Inc. (0000310158) (Filer)
424B5 - Merck & Co., Inc. (0000310158) (Filer)
424B5 - Merck & Co., Inc. (0000310158) (Filer)
Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00
Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00
Citigroup downgraded Merck from Buy to Neutral and set a new price target of $84.00
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2025 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, Oct. 30. During the call, company executives will provide an overview of Merck's performance for the quarter. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialing (800) 369-3351 (U.S. and Canada Toll-Fr
Total Worldwide Sales Were $15.8 Billion, a Decrease of 2% From Second Quarter 2024 Both Nominally and Excluding the Impact of Foreign Exchange KEYTRUDA Sales Were $8.0 Billion, Growth of 9% Both Nominally and Excluding the Impact of Foreign Exchange WINREVAIR Sales Were $336 Million Animal Health Sales Were $1.6 Billion, Growth of 11% Both Nominally and Excluding the Impact of Foreign Exchange GARDASIL/GARDASIL 9 Sales Were $1.1 Billion, a Decline of 55% Both Nominally and Excluding the Impact of Foreign Exchange GAAP EPS Was $1.76; Non-GAAP EPS Was $2.13; GAAP and Non-GAAP EPS Include a Charge of $0.07 per Share for Closing of Hengrui Pharma License Agreement Announce
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the fourth quarter of 2025. Payment will be made on Oct. 7, 2025 to shareholders of record at the close of business on Sept. 15, 2025. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-inten
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua